Maria E Lund
Overview
Explore the profile of Maria E Lund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghosh S, Fletcher N, Huda P, Houston Z, Howard C, Lund M, et al.
Mol Pharm
. 2023 Jan;
20(3):1549-1563.
PMID: 36602058
Glioblastoma (GBM) is the most aggressive form of primary brain cancer, accounting for about 85% of all primary central nervous system (CNS) tumors. With standard treatment strategies like surgery, radiation,...
2.
Sabanathan D, Lund M, Campbell D, Walsh B, Gurney H
Ther Adv Med Oncol
. 2021 Oct;
13:17588359211022918.
PMID: 34646364
Radioimmunotherapy (i.e., the use of radiolabeled tumor targeting antibodies) is an emerging approach for the diagnosis, therapy, and monitoring of solid tumors. Often using paired agents, each targeting the same...
3.
Polikarpov D, Campbell D, Zaslavsky A, Lund M, Wu A, Lu Y, et al.
Int J Urol
. 2021 Sep;
28(12):1290-1297.
PMID: 34498294
Objectives: To investigate whether anti-glypican-1 antibody Miltuximab conjugated with near-infrared dye IRDye800CW can be used for in vivo fluorescence imaging of urothelial carcinoma. Methods: The conjugate, Miltuximab-IRDye800CW, was produced and...
4.
Sabanathan D, Campbell D, Velonas V, Wissmueller S, Mazure H, Trifunovic M, et al.
Asia Ocean J Nucl Med Biol
. 2021 Jul;
9(2):86-100.
PMID: 34250138
Objectives: Miltuximab is a chimeric antibody targeting Glypican-1 (GPC-1), a cell surface antigen which is overexpressed in solid cancers. Miltuximab has shown promising safety and efficacy in radioimmunotherapy models of...
5.
Lund M, Howard C, Thurecht K, Campbell D, Mahler S, Walsh B
BMC Cancer
. 2020 Dec;
20(1):1214.
PMID: 33302918
Background: Glypican-1 is a heparan sulfate proteoglycan that is overexpressed in prostate cancer (PCa), and a variety of solid tumors. Importantly, expression is restricted in normal tissue, making it an...
6.
Polikarpov D, Campbell D, Lund M, Lu Y, Lu Y, Wu J, et al.
Photodiagnosis Photodyn Ther
. 2020 Oct;
32:102064.
PMID: 33069874
Background: Photoimmunotherapy (PIT) is an emerging method of cancer treatment based on the use of a photosensitizer near-infrared dye IRDye700DX (IR700) conjugated to a monoclonal antibody. The antibody selectively delivers...
7.
Polikarpov D, Campbell D, McRobb L, Wu J, Lund M, Lu Y, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32316186
Glioblastoma (GBM) is one of the most aggressive tumors and its 5-year survival is approximately 5%. Fluorescence-guided surgery (FGS) improves the extent of resection and leads to better prognosis. Molecular...
8.
Lund M, Campbell D, Walsh B
Adv Exp Med Biol
. 2020 Apr;
1245:163-176.
PMID: 32266658
Glypican-1 (GPC-1) is a cell surface heparan sulphate proteoglycan that is critical during normal development, but which is not required for normal homoeostasis in the adult. It is, however, overexpressed...
9.
Levin R, Lund M, Truong Q, Wu A, Shore N, Saltzstein D, et al.
Oncotarget
. 2018 Jun;
9(32):22359-22367.
PMID: 29854284
Prostate cancer is responsible for hundreds of thousands of annual deaths worldwide. The current gold standard in early detection of prostate cancer, the prostate specific antigen test, boasts a high...
10.
Campbell D, Lund M, Nocon A, Cozzi P, Frydenberg M, de Souza P, et al.
PLoS One
. 2018 Apr;
13(4):e0196017.
PMID: 29672570
While measurement of serum prostate specific antigen (PSA) is an important screening tool for prostate cancer, new biomarkers are necessary for better discrimination between presence and absence of disease. The...